Stereotaxis, Inc. (STXS) announced on April 14, 2026 that it has entered into a definitive agreement to acquire Robocath, a French venture‑backed company that develops robotic systems for interventional cardiology and neurointerventions. The transaction is valued at up to $45 million, consisting of an upfront cash payment of $20 million and up to $25 million in contingent payments tied to regulatory approvals and commercial milestones, with an expected closing in mid‑2026.
Robocath’s flagship R‑One+™ system is the only commercially available robotic platform for percutaneous coronary interventions in Europe, with fifteen installations worldwide. The company was founded in 2009 and has raised between $57.9 million and $87.9 million in funding. Its R‑One+ was launched in May 2023 and offers radiation protection for staff and enhanced procedural precision.
Stereotaxis has built a portfolio of magnetic‑navigation systems, including GenesisX, Synchrony, and SynX. In Q4 2025 the company generated $8.6 million in revenue, a 36% year‑over‑year increase, and $32.4 million in full‑year 2025 revenue, up 20% from 2024. The acquisition is part of a strategic shift from a capital‑equipment vendor to a high‑margin disposable platform, aimed at broadening the addressable market into coronary and neurovascular procedures.
Management estimates that Robocath will contribute approximately $2 million in annual revenue in the first year after closing and expects the acquisition to reach breakeven within three years. The deal will allow Stereotaxis to combine its magnetic‑navigation platform with Robocath’s mechanical robotics, creating a fully integrated solution capable of manipulating multiple devices simultaneously—a capability that is currently unique in the market.
David Fischel, Stereotaxis Chairman and CEO, said, "Robocath represents a highly strategic addition to Stereotaxis, amplifying and accelerating our strategy as the leading robotic platform for the broad spectrum of endovascular procedures." Philippe Bencteux, Robocath founder and CEO, added, "Joining Stereotaxis provides the scale, complementary technologies, and strategic alignment needed to accelerate our development and expand our impact."
Investors reacted positively to the announcement, reflecting confidence in the strategic fit and potential for growth. The acquisition positions Stereotaxis to compete more effectively against larger med‑tech players with integrated systems and expands its reach into the tens‑of‑billions‑of‑dollars‑per‑year interventional cardiology and neurointerventional markets.
The integration of Robocath’s mechanical robotics with Stereotaxis’ magnetic‑navigation platform will enable the combined entity to offer a unique, fully integrated robotic solution that can manipulate multiple devices simultaneously. This expansion into coronary and neurovascular procedures is expected to create new revenue streams, enhance cross‑sell opportunities, and accelerate the company’s transition to a high‑margin disposable platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.